VKTX Viking Therapeutics Inc
Price (delayed)
$67.47
Market cap
$7.48B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.94
Enterprise value
$7.43B
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, orally available, first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and
Highlights
VKTX's equity has surged by 139% year-on-year
The company's quick ratio rose by 29% YoY and by 28% QoQ
The net income fell by 31% YoY and by 3.2% QoQ
The EPS has declined by 3.3% year-on-year
Key stats
What are the main financial stats of VKTX
Market
Valuations
Earnings
Shares outstanding
110.8M
Market cap
$7.48B
Enterprise value
$7.43B
Price to earnings (P/E)
N/A
Price to book (P/B)
8.08
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$96.75M
EBITDA
-$96.45M
Free cash flow
-$71.95M
Per share
Balance sheet
Liquidity
EPS
-$0.94
Free cash flow per share
-$0.65
Book value per share
$8.35
Revenue per share
$0
TBVPS
$8.58
Total assets
$946.84M
Total liabilities
$25.86M
Debt
$1.1M
Equity
$920.98M
Working capital
$920.63M
Debt to equity
0
Current ratio
37.69
Quick ratio
37.55
Net debt/EBITDA
0.44
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-14.5%
Return on equity
-15%
Return on invested capital
-17.2%
Return on capital employed
-10.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VKTX stock price
How has the Viking Therapeutics stock price performed over time
Intraday
1.11%
1 week
23.17%
1 month
18.97%
1 year
356.8%
YTD
262.55%
QTD
27.28%
Financial performance
How have Viking Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$124.68M
Net income
-$96.75M
Gross margin
N/A
Net margin
N/A
Viking Therapeutics's operating income has plunged by 54% YoY and by 9% from the previous quarter
The net income fell by 31% YoY and by 3.2% QoQ
Growth
What is Viking Therapeutics's growth rate over time
Valuation
What is Viking Therapeutics stock price valuation
P/E
N/A
P/B
8.08
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has declined by 3.3% year-on-year
The P/B is 142% more than the 5-year quarterly average of 3.3 and 35% more than the last 4 quarters average of 5.9
VKTX's equity has surged by 139% year-on-year
Efficiency
How efficient is Viking Therapeutics business performance
The ROIC has soared by 61% year-on-year and by 23% since the previous quarter
Viking Therapeutics's ROE has soared by 59% YoY and by 18% from the previous quarter
VKTX's ROA has soared by 57% year-on-year and by 18% since the previous quarter
Dividends
What is VKTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VKTX.
Financial health
How did Viking Therapeutics financials performed over time
The total assets has soared by 136% YoY but it has contracted by 2.1% from the previous quarter
VKTX's total liabilities has soared by 77% YoY but it is down by 23% from the previous quarter
Viking Therapeutics's debt is 100% lower than its equity
VKTX's equity has surged by 139% year-on-year
Viking Therapeutics's debt has decreased by 22% YoY and by 7% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.